FFAR2 and cancer: Several GPR43 agonists have been reported, such as 4-chloro-α-(1-methylethyl)-N-2-thiazolylbenzeneacetamide (4-CMTB) and AZ1729, but only in preclinical studies in the field of inflammation, its role in cancers is still unknown.167–170